Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Midodrine
- Accession Number
- DB00211 (APRD01116)
- Type
- Small Molecule
- Groups
- Approved
- Description
An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. [PubChem]
- Structure
Structure for DB00211 (Midodrine)
- Synonyms
- (+-)-2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide
- 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol
- 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide
- DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid
- Midodrin
- Midodrina
- Midodrinum
- Product Ingredients
Ingredient UNII CAS InChI Key Midodrine hydrochloride 59JV96YTXV 43218-56-0 MGCQZNBCJBRZDT-UHFFFAOYSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Amatine Tablet 5 mg Oral Shire Pharma Canada Ulc 1992-12-31 2010-10-04 Canada 
Amatine Tablet 2.5 mg Oral Shire Pharma Canada Ulc 1992-12-31 2010-09-30 Canada Midodrine Tablet 5.0 mg Oral Aa Pharma Inc 2006-06-13 Not applicable Canada Midodrine Tablet 2.5 mg Oral Aa Pharma Inc 2006-06-13 Not applicable Canada ProAmatine Tablet 2.5 mg/1 Oral Shire 1996-09-06 2017-12-22 US 
ProAmatine Tablet 10 mg/1 Oral Shire 2002-03-20 2017-12-22 US ProAmatine Tablet 5 mg/1 Oral Shire 1996-09-06 2017-12-22 US ProAmatine Tablet 5 mg/1 Oral Physicians Total Care, Inc. 2005-09-30 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Mar-midodrine Tablet 2.5 mg Oral Marcan Pharmaceuticals Inc Not applicable Not applicable Canada Mar-midodrine Tablet 5 mg Oral Marcan Pharmaceuticals Inc Not applicable Not applicable Canada Midodrine HCl Tablet 10 mg/1 Oral Rebel Distributors 2002-07-02 Not applicable US 
Midodrine HCl Tablet 5 mg/1 Oral Cardinal Health 2004-11-03 Not applicable US 
Midodrine HCl Tablet 5 mg/1 Oral Amerincan Health Packaging 2010-05-11 Not applicable US Midodrine HCl Tablet 5 mg/1 Oral Eon Labs, Inc. 2003-09-11 Not applicable US Midodrine HCl Tablet 5 mg/1 Oral Cardinal Health 2012-11-26 Not applicable US Midodrine HCl Tablet 2.5 mg/1 Oral Amerincan Health Packaging 2010-05-11 Not applicable US Midodrine HCl Tablet 2.5 mg/1 Oral Cardinal Health 2010-05-11 Not applicable US Midodrine HCl Tablet 2.5 mg/1 Oral Eon Labs, Inc. 2003-09-11 Not applicable US - Categories
- Adrenergic Agents
- Adrenergic Agonists
- Adrenergic alpha-1 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic and Dopaminergic Agents
- Alcohols
- Amines
- Amino Alcohols
- Autonomic Agents
- Cardiac Stimulants Excl. Cardiac Glycosides
- Cardiac Therapy
- Cardiovascular Agents
- Cardiovascular System
- Cytochrome P-450 Enzyme Inhibitors
- Ethanolamines
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Sympathomimetics
- Vasoconstrictor Agents
- UNII
- 6YE7PBM15H
- CAS number
- 42794-76-3
- Weight
- Average: 254.2823
Monoisotopic: 254.126657074 - Chemical Formula
- C12H18N2O4
- InChI Key
- PTKSEFOSCHHMPD-UHFFFAOYSA-N
- InChI
- InChI=1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)
- IUPAC Name
- 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide
- SMILES
- COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1
Pharmacology
- Indication
For the treatment of symptomatic orthostatic hypotension (OH).
- Associated Conditions
- Pharmacodynamics
Midodrine is a prodrug, i.e., the therapeutic effect of orally administered midodrine is due to the major metabolite desglymidodrine formed by deglycination of midodrine. Desglymidodrine diffuses poorly across the blood-brain barrier, and is therefore not associated with effects on the central nervous system. Administration of midodrine results in a rise in standing, sitting, and supine systolic and diastolic blood pressure in patients with orthostatic hypotension of various etiologies. Standing systolic blood pressure is elevated by approximately 15 to 30 mmHg at 1 hour after a 10-mg dose of midodrine, with some effect persisting for 2 to 3 hours. Midodrine has no clinically significant effect on standing or supine pulse rates in patients with autonomic failure.
- Mechanism of action
Midodrine forms an active metabolite, desglymidodrine, that is an alpha1-agonist, and exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure. Desglymidodrine does not stimulate cardiac beta-adrenergic receptors.
Target Actions Organism AAlpha-1A adrenergic receptor agonistHuman AAlpha-1B adrenergic receptor agonistHuman UAlpha-1D adrenergic receptor agonistHuman - Absorption
Rapidly absorbed following oral administration. The absolute bioavailability of midodrine (measured as desglymidodrine) is 93% and is not affected by food.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Thorough metabolic studies have not been conducted, but it appears that deglycination of midodrine to desglymidodrine takes place in many tissues, and both compounds are metabolized in part by the liver.
- Route of elimination
- Not Available
- Half life
The plasma levels of the prodrug peak after about half an hour, and decline with a half-life of approximately 25 minutes, while the metabolite reaches peak blood concentrations about 1 to 2 hours after a dose of midodrine and has a half-life of about 3 to 4 hours.
- Clearance
- Renal cl=385 mL/minute
- Toxicity
Symptoms of overdose could include hypertension, piloerection (goosebumps), a sensation of coldness and urinary retention. The single doses that would be associated with symptoms of overdosage or would be potentially life- threatening are unknown. The oral LD50 is approximately 30 to 50 mg/kg in rats, 675 mg/kg in mice, and 125 to 160 mg/kg in dogs. Desglymidodrine is dialyzable.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Midodrine. Experimental Acebutolol Acebutolol may increase the bradycardic activities of Midodrine. Approved, Investigational Acepromazine Acepromazine may decrease the vasoconstricting activities of Midodrine. Approved, Vet Approved Acetyldigitoxin Acetyldigitoxin may increase the bradycardic activities of Midodrine. Approved Acetyldigoxin Acetyldigoxin may increase the bradycardic activities of Midodrine. Experimental Alfuzosin Alfuzosin may decrease the vasoconstricting activities of Midodrine. Approved, Investigational Alprenolol Alprenolol may increase the bradycardic activities of Midodrine. Approved, Withdrawn Amineptine Amineptine may increase the vasopressor activities of Midodrine. Illicit, Withdrawn Amitriptyline Amitriptyline may increase the vasopressor activities of Midodrine. Approved Amitriptylinoxide Amitriptylinoxide may increase the vasopressor activities of Midodrine. Approved, Investigational Amoxapine Amoxapine may increase the vasopressor activities of Midodrine. Approved Amphetamine Amphetamine may increase the hypertensive activities of Midodrine. Approved, Illicit, Investigational Aripiprazole Aripiprazole may decrease the vasoconstricting activities of Midodrine. Approved, Investigational Arotinolol Arotinolol may increase the bradycardic activities of Midodrine. Investigational Asenapine Asenapine may increase the bradycardic activities of Midodrine. Approved Atenolol Atenolol may increase the bradycardic activities of Midodrine. Approved Atomoxetine Atomoxetine may increase the hypertensive activities of Midodrine. Approved Befunolol Befunolol may increase the bradycardic activities of Midodrine. Experimental Benmoxin Benmoxin may increase the hypertensive activities of Midodrine. Withdrawn Benzphetamine The risk or severity of adverse effects can be increased when Midodrine is combined with Benzphetamine. Approved, Illicit Benzylpenicilloyl Polylysine Midodrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent. Approved Betaxolol Betaxolol may increase the bradycardic activities of Midodrine. Approved, Investigational Bevantolol Bevantolol may increase the bradycardic activities of Midodrine. Approved Bisoprolol Bisoprolol may increase the bradycardic activities of Midodrine. Approved Bopindolol Bopindolol may increase the bradycardic activities of Midodrine. Approved Brexpiprazole Brexpiprazole may decrease the vasoconstricting activities of Midodrine. Approved, Investigational Brofaromine Brofaromine may increase the hypertensive activities of Midodrine. Experimental Bromocriptine Bromocriptine may increase the hypertensive activities of Midodrine. Approved, Investigational Bucindolol Bucindolol may increase the bradycardic activities of Midodrine. Investigational Bufuralol Bufuralol may increase the bradycardic activities of Midodrine. Experimental, Investigational Bunazosin Bunazosin may decrease the vasoconstricting activities of Midodrine. Investigational Bupranolol Bupranolol may increase the bradycardic activities of Midodrine. Approved Butriptyline Butriptyline may increase the vasopressor activities of Midodrine. Approved Cabergoline Cabergoline may increase the hypertensive activities of Midodrine. Approved Caffeine The risk or severity of adverse effects can be increased when Midodrine is combined with Caffeine. Approved Caroxazone Caroxazone may increase the hypertensive activities of Midodrine. Withdrawn Carteolol Carteolol may increase the bradycardic activities of Midodrine. Approved Celiprolol Celiprolol may increase the bradycardic activities of Midodrine. Approved, Investigational Chlorphentermine The risk or severity of adverse effects can be increased when Midodrine is combined with Chlorphentermine. Illicit, Withdrawn Chlorpromazine Chlorpromazine may decrease the vasoconstricting activities of Midodrine. Approved, Investigational, Vet Approved Clenbuterol The risk or severity of adverse effects can be increased when Midodrine is combined with Clenbuterol. Approved, Investigational, Vet Approved Clomipramine Clomipramine may increase the vasopressor activities of Midodrine. Approved, Investigational, Vet Approved Cloranolol Cloranolol may increase the bradycardic activities of Midodrine. Experimental Clozapine Clozapine may decrease the vasoconstricting activities of Midodrine. Approved Cyclobenzaprine Cyclobenzaprine may increase the vasopressor activities of Midodrine. Approved Dapiprazole Dapiprazole may decrease the vasoconstricting activities of Midodrine. Approved Deslanoside Deslanoside may increase the bradycardic activities of Midodrine. Approved Desvenlafaxine Desvenlafaxine may increase the tachycardic activities of Midodrine. Approved, Investigational Dextroamphetamine Dextroamphetamine may decrease the vasoconstricting activities of Midodrine. Approved, Illicit Dibenzepin Dibenzepin may increase the vasopressor activities of Midodrine. Experimental Diethylpropion The risk or severity of adverse effects can be increased when Midodrine is combined with Diethylpropion. Approved, Illicit Digoxin Digoxin may increase the bradycardic activities of Midodrine. Approved Digoxin Immune Fab (Ovine) Digoxin Immune Fab (Ovine) may increase the bradycardic activities of Midodrine. Approved Dihydroergocornine Dihydroergocornine may increase the hypertensive activities of Midodrine. Approved Dihydroergocristine Dihydroergocristine may increase the hypertensive activities of Midodrine. Approved, Experimental Dihydroergocryptine Dihydroergocryptine may increase the hypertensive activities of Midodrine. Experimental Dihydroergotamine Dihydroergotamine may increase the hypertensive activities of Midodrine. Approved, Investigational Diltiazem Diltiazem may increase the bradycardic activities of Midodrine. Approved, Investigational Dimetacrine Dimetacrine may increase the vasopressor activities of Midodrine. Approved, Withdrawn Dobutamine The risk or severity of adverse effects can be increased when Midodrine is combined with Dobutamine. Approved Dopamine The risk or severity of adverse effects can be increased when Midodrine is combined with Dopamine. Approved Dosulepin Dosulepin may increase the vasopressor activities of Midodrine. Approved Doxazosin The therapeutic efficacy of Midodrine can be decreased when used in combination with Doxazosin. Approved Doxepin Doxepin may increase the vasopressor activities of Midodrine. Approved, Investigational Doxofylline The risk or severity of adverse effects can be increased when Midodrine is combined with Doxofylline. Approved, Investigational Dronabinol Dronabinol may increase the tachycardic activities of Midodrine. Approved, Illicit Dronedarone Dronedarone may decrease the vasoconstricting activities of Midodrine. Approved Droperidol Droperidol may decrease the vasoconstricting activities of Midodrine. Approved, Vet Approved Droxidopa Midodrine may increase the hypertensive activities of Droxidopa. Approved, Investigational Duloxetine Duloxetine may increase the tachycardic activities of Midodrine. Approved Epanolol Epanolol may increase the bradycardic activities of Midodrine. Experimental Ephedrine The risk or severity of adverse effects can be increased when Midodrine is combined with Ephedrine. Approved Epinephrine The risk or severity of adverse effects can be increased when Midodrine is combined with Epinephrine. Approved, Vet Approved Ergoloid mesylate Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Midodrine. Approved Ergonovine Ergonovine may increase the hypertensive activities of Midodrine. Approved Ergotamine Ergotamine may increase the hypertensive activities of Midodrine. Approved Esatenolol Esatenolol may increase the bradycardic activities of Midodrine. Experimental Escitalopram Escitalopram may decrease the vasoconstricting activities of Midodrine. Approved, Investigational Esmolol Esmolol may increase the bradycardic activities of Midodrine. Approved Etilefrine The risk or severity of adverse effects can be increased when Midodrine is combined with Etilefrine. Withdrawn Fenoterol The risk or severity of adverse effects can be increased when Midodrine is combined with Fenoterol. Approved, Investigational Fenozolone The risk or severity of adverse effects can be increased when Midodrine is combined with Fenozolone. Experimental Fentanyl The serum concentration of Fentanyl can be decreased when it is combined with Midodrine. Approved, Illicit, Investigational, Vet Approved Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Midodrine. Approved Flupentixol Flupentixol may decrease the vasoconstricting activities of Midodrine. Approved, Investigational, Withdrawn Furazolidone Furazolidone may increase the hypertensive activities of Midodrine. Approved, Investigational, Vet Approved Ganciclovir The risk or severity of adverse effects can be increased when Midodrine is combined with Ganciclovir. Approved, Investigational Gitoformate Gitoformate may increase the bradycardic activities of Midodrine. Experimental Harmaline Harmaline may increase the hypertensive activities of Midodrine. Experimental Hyaluronidase Hyaluronidase may increase the vasoconstricting activities of Midodrine. Approved, Investigational Hydracarbazine Hydracarbazine may increase the hypertensive activities of Midodrine. Experimental Hydroxyamphetamine The risk or severity of adverse effects can be increased when Midodrine is combined with Hydroxyamphetamine. Approved Iloperidone Iloperidone may decrease the vasoconstricting activities of Midodrine. Approved Imipramine Imipramine may increase the vasopressor activities of Midodrine. Approved Indenolol Indenolol may increase the bradycardic activities of Midodrine. Withdrawn Indoramin Indoramin may decrease the vasoconstricting activities of Midodrine. Withdrawn Iobenguane The therapeutic efficacy of Iobenguane can be decreased when used in combination with Midodrine. Approved, Investigational Iprindole Iprindole may increase the vasopressor activities of Midodrine. Experimental Iproclozide Iproclozide may increase the hypertensive activities of Midodrine. Withdrawn Iproniazid Iproniazid may increase the hypertensive activities of Midodrine. Withdrawn Isocarboxazid Isocarboxazid may increase the hypertensive activities of Midodrine. Approved Isoprenaline The risk or severity of adverse effects can be increased when Midodrine is combined with Isoprenaline. Approved, Investigational Isoxsuprine The risk or severity of adverse effects can be increased when Midodrine is combined with Isoxsuprine. Approved, Withdrawn Labetalol Labetalol may increase the bradycardic activities of Midodrine. Approved Lanatoside C Lanatoside C may increase the bradycardic activities of Midodrine. Experimental Landiolol Landiolol may increase the bradycardic activities of Midodrine. Investigational Levobetaxolol Levobetaxolol may increase the bradycardic activities of Midodrine. Approved, Investigational Levobunolol Levobunolol may increase the bradycardic activities of Midodrine. Approved Levomilnacipran Levomilnacipran may increase the tachycardic activities of Midodrine. Approved, Investigational Linezolid Linezolid may increase the hypertensive activities of Midodrine. Approved, Investigational Lisdexamfetamine Lisdexamfetamine may decrease the vasoconstricting activities of Midodrine. Approved, Investigational Lisuride Lisuride may increase the hypertensive activities of Midodrine. Approved, Investigational Lofepramine Lofepramine may increase the vasopressor activities of Midodrine. Experimental Lysergic Acid Diethylamide Lysergic Acid Diethylamide may increase the hypertensive activities of Midodrine. Illicit, Investigational, Withdrawn Mebanazine Mebanazine may increase the hypertensive activities of Midodrine. Withdrawn Mefenorex The risk or severity of adverse effects can be increased when Midodrine is combined with Mefenorex. Experimental Melitracen Melitracen may increase the vasopressor activities of Midodrine. Experimental, Investigational Mephentermine The risk or severity of adverse effects can be increased when Midodrine is combined with Mephentermine. Approved Mepindolol Mepindolol may increase the bradycardic activities of Midodrine. Experimental Metaraminol The risk or severity of adverse effects can be increased when Midodrine is combined with Metaraminol. Approved, Investigational Metergoline Metergoline may increase the hypertensive activities of Midodrine. Experimental Methamphetamine The risk or severity of adverse effects can be increased when Midodrine is combined with Methamphetamine. Approved, Illicit Methotrimeprazine Methotrimeprazine may decrease the vasoconstricting activities of Midodrine. Approved, Investigational Methoxamine The risk or severity of adverse effects can be increased when Midodrine is combined with Methoxamine. Approved, Investigational Methylene blue Methylene blue may increase the hypertensive activities of Midodrine. Approved, Investigational Methylergometrine Methylergometrine may increase the hypertensive and vasoconstricting activities of Midodrine. Approved Methysergide Methysergide may increase the hypertensive activities of Midodrine. Approved Metildigoxin Metildigoxin may increase the bradycardic activities of Midodrine. Experimental Metipranolol Metipranolol may increase the bradycardic activities of Midodrine. Approved Milnacipran Milnacipran may increase the tachycardic activities of Midodrine. Approved, Investigational Minaprine Minaprine may increase the hypertensive activities of Midodrine. Approved Moclobemide Moclobemide may increase the hypertensive activities of Midodrine. Approved, Investigational Nabilone Nabilone may increase the tachycardic activities of Midodrine. Approved, Investigational Nadolol Nadolol may increase the bradycardic activities of Midodrine. Approved Nebivolol Nebivolol may increase the bradycardic activities of Midodrine. Approved, Investigational Nefazodone Nefazodone may decrease the vasoconstricting activities of Midodrine. Approved, Withdrawn Nialamide Nialamide may increase the hypertensive activities of Midodrine. Withdrawn Nicardipine The therapeutic efficacy of Midodrine can be decreased when used in combination with Nicardipine. Approved, Investigational Nicergoline Nicergoline may increase the hypertensive activities of Midodrine. Approved, Investigational Niguldipine The therapeutic efficacy of Midodrine can be decreased when used in combination with Niguldipine. Experimental Norepinephrine The risk or severity of adverse effects can be increased when Midodrine is combined with Norepinephrine. Approved Nortriptyline Nortriptyline may increase the vasopressor activities of Midodrine. Approved Nylidrin The risk or severity of adverse effects can be increased when Midodrine is combined with Nylidrin. Approved Octamoxin Octamoxin may increase the hypertensive activities of Midodrine. Withdrawn Olanzapine Olanzapine may decrease the vasoconstricting activities of Midodrine. Approved, Investigational Oleandrin Oleandrin may increase the bradycardic activities of Midodrine. Experimental, Investigational Opipramol Opipramol may increase the vasopressor activities of Midodrine. Investigational Orciprenaline The risk or severity of adverse effects can be increased when Midodrine is combined with Orciprenaline. Approved Oxprenolol Oxprenolol may increase the bradycardic activities of Midodrine. Approved Oxymetazoline The risk or severity of adverse effects can be increased when Midodrine is combined with Oxymetazoline. Approved, Investigational Paliperidone Paliperidone may decrease the vasoconstricting activities of Midodrine. Approved Pargyline Pargyline may increase the hypertensive activities of Midodrine. Approved Patent Blue The therapeutic efficacy of Midodrine can be decreased when used in combination with Patent Blue. Approved Penbutolol Penbutolol may increase the bradycardic activities of Midodrine. Approved, Investigational Pergolide Pergolide may increase the hypertensive activities of Midodrine. Approved, Investigational, Vet Approved, Withdrawn Peruvoside Peruvoside may increase the bradycardic activities of Midodrine. Experimental Phenelzine Phenelzine may increase the hypertensive activities of Midodrine. Approved Pheniprazine Pheniprazine may increase the hypertensive activities of Midodrine. Withdrawn Phenmetrazine The risk or severity of adverse effects can be increased when Midodrine is combined with Phenmetrazine. Approved, Illicit Phenoxybenzamine Phenoxybenzamine may decrease the vasoconstricting activities of Midodrine. Approved Phenoxypropazine Phenoxypropazine may increase the hypertensive activities of Midodrine. Withdrawn Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Midodrine. Approved, Illicit Phentolamine Phentolamine may decrease the vasoconstricting activities of Midodrine. Approved Phenylephrine The risk or severity of adverse effects can be increased when Midodrine is combined with Phenylephrine. Approved Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Midodrine. Approved, Vet Approved, Withdrawn Pindolol Pindolol may increase the bradycardic activities of Midodrine. Approved, Investigational Pirlindole Pirlindole may increase the hypertensive activities of Midodrine. Approved Pitolisant The serum concentration of Pitolisant can be increased when it is combined with Midodrine. Approved, Investigational Pivhydrazine Pivhydrazine may increase the hypertensive activities of Midodrine. Withdrawn Pizotifen Pizotifen may decrease the vasoconstricting activities of Midodrine. Approved Platelet Activating Factor Platelet Activating Factor may increase the bradycardic activities of Midodrine. Experimental Practolol Practolol may increase the bradycardic activities of Midodrine. Approved Prazosin Prazosin may decrease the vasoconstricting activities of Midodrine. Approved Prenalterol The risk or severity of adverse effects can be increased when Midodrine is combined with Prenalterol. Experimental Procaine Procaine may increase the hypertensive activities of Midodrine. Approved, Investigational, Vet Approved Procarbazine Procarbazine may increase the hypertensive activities of Midodrine. Approved, Investigational Procaterol The risk or severity of adverse effects can be increased when Midodrine is combined with Procaterol. Approved, Investigational Promazine Promazine may decrease the vasoconstricting activities of Midodrine. Approved, Vet Approved Propericiazine Propericiazine may decrease the vasoconstricting activities of Midodrine. Approved, Investigational Propiomazine Propiomazine may decrease the vasoconstricting activities of Midodrine. Approved Propiverine Propiverine may decrease the vasoconstricting activities of Midodrine. Approved, Investigational Proscillaridin Proscillaridin may increase the bradycardic activities of Midodrine. Experimental Protriptyline Protriptyline may increase the vasopressor activities of Midodrine. Approved Pseudoephedrine The risk or severity of adverse effects can be increased when Midodrine is combined with Pseudoephedrine. Approved Quetiapine The therapeutic efficacy of Midodrine can be decreased when used in combination with Quetiapine. Approved Quinidine Quinidine may decrease the vasoconstricting activities of Midodrine. Approved, Investigational Racepinephrine The risk or severity of adverse effects can be increased when Midodrine is combined with Racepinephrine. Approved Rasagiline Rasagiline may increase the hypertensive activities of Midodrine. Approved Risperidone Risperidone may decrease the vasoconstricting activities of Midodrine. Approved, Investigational Ritodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Ritodrine. Approved, Investigational Safrazine Safrazine may increase the hypertensive activities of Midodrine. Withdrawn Selegiline Selegiline may increase the hypertensive activities of Midodrine. Approved, Investigational, Vet Approved Silodosin Silodosin may decrease the vasoconstricting activities of Midodrine. Approved Sotalol Sotalol may increase the bradycardic activities of Midodrine. Approved Spironolactone The therapeutic efficacy of Midodrine can be decreased when used in combination with Spironolactone. Approved Synephrine The risk or severity of adverse effects can be increased when Midodrine is combined with Synephrine. Experimental Talinolol Talinolol may increase the bradycardic activities of Midodrine. Investigational Tamsulosin Tamsulosin may decrease the vasoconstricting activities of Midodrine. Approved, Investigational Tedizolid phosphate Tedizolid Phosphate may increase the hypertensive activities of Midodrine. Approved Terazosin Terazosin may decrease the vasoconstricting activities of Midodrine. Approved Terbutaline Terbutaline may increase the bradycardic activities of Midodrine. Approved Terguride Terguride may increase the hypertensive activities of Midodrine. Experimental Tertatolol Tertatolol may increase the bradycardic activities of Midodrine. Experimental Tetryzoline The risk or severity of adverse effects can be increased when Midodrine is combined with Tetryzoline. Approved Thioproperazine Thioproperazine may decrease the vasoconstricting activities of Midodrine. Approved Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Midodrine. Approved, Withdrawn Tianeptine Tianeptine may increase the vasopressor activities of Midodrine. Approved, Investigational Timolol Timolol may increase the bradycardic activities of Midodrine. Approved Tolazoline Tolazoline may decrease the vasoconstricting activities of Midodrine. Approved, Vet Approved Toloxatone Toloxatone may increase the hypertensive activities of Midodrine. Approved Tramazoline The risk or severity of adverse effects can be increased when Midodrine is combined with Tramazoline. Investigational Tranylcypromine Tranylcypromine may increase the hypertensive activities of Midodrine. Approved, Investigational Trazodone Trazodone may decrease the vasoconstricting activities of Midodrine. Approved, Investigational Tretoquinol The risk or severity of adverse effects can be increased when Midodrine is combined with Tretoquinol. Experimental Trifluoperazine Trifluoperazine may decrease the vasoconstricting activities of Midodrine. Approved, Investigational Trimazosin Trimazosin may decrease the vasoconstricting activities of Midodrine. Experimental Trimipramine Trimipramine may increase the vasopressor activities of Midodrine. Approved Tyramine The risk or severity of adverse effects can be increased when Midodrine is combined with Tyramine. Investigational, Nutraceutical Urapidil Urapidil may decrease the vasoconstricting activities of Midodrine. Investigational Valaciclovir The risk or severity of adverse effects can be increased when Midodrine is combined with Valaciclovir. Approved, Investigational Venlafaxine Venlafaxine may increase the tachycardic activities of Midodrine. Approved Verapamil Verapamil may increase the bradycardic activities of Midodrine. Approved WIN 55212-2 The risk or severity of Tachycardia can be increased when WIN 55212-2 is combined with Midodrine. Experimental Ziprasidone Ziprasidone may decrease the vasoconstricting activities of Midodrine. Approved Zuclopenthixol Zuclopenthixol may decrease the vasoconstricting activities of Midodrine. Approved, Investigational - Food Interactions
- Take without regard to meals.
References
- Synthesis Reference
Anup K. Ray, Hiren Patel, Mahendra R. Patel, "Synthesis of midodrine HCI from a novel intermediate 1-(2',5'-dimethoxyphenyl)-2-azidoethanone." U.S. Patent US6201153, issued July, 1965.
US6201153- General References
- Hebenstreit G: [Treatment of hypotension caused by psychopharmacological drugs (author's transl)]. Wien Med Wochenschr. 1981 Feb 28;131(4):109-12. [PubMed:6165144]
- Tsuda M, Terada T, Irie M, Katsura T, Niida A, Tomita K, Fujii N, Inui K: Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. Epub 2006 Apr 5. [PubMed:16597710]
- External Links
- Human Metabolome Database
- HMDB0014356
- KEGG Compound
- C07890
- PubChem Compound
- 4195
- PubChem Substance
- 46507373
- ChemSpider
- 4050
- ChEBI
- 6933
- ChEMBL
- CHEMBL1201212
- Therapeutic Targets Database
- DAP000229
- PharmGKB
- PA164749381
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Midodrine
- ATC Codes
- C01CA17 — Midodrine
- AHFS Codes
- 12:12.04 — Alpha-adrenergic Agonists
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Apotex inc etobicoke site
- Impax pharmaceuticals
- Mylan pharmaceuticals inc
- Sandoz inc
- Upsher smith laboratories inc
- Shire development inc
- Packagers
- Actavis Group
- Amerisource Health Services Corp.
- Apotex Inc.
- Eon Labs
- Global Pharmaceuticals
- Heartland Repack Services LLC
- Impax Laboratories Inc.
- Kaiser Foundation Hospital
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Nycomed Inc.
- Physicians Total Care Inc.
- Rebel Distributors Corp.
- Resource Optimization and Innovation LLC
- Shire Inc.
- UDL Laboratories
- Upsher Smith Laboratories
- Vangard Labs Inc.
- Dosage forms
Form Route Strength Tablet Oral 5 mg Tablet Oral 2.5 mg Tablet Oral 5.0 mg Tablet Oral 10 mg/1 Tablet Oral 2.5 mg/1 Tablet Oral 5 mg/1 - Prices
Unit description Cost Unit Proamatine 10 mg tablet 5.91USD tablet Midodrine hcl 10 mg tablet 4.93USD tablet Proamatine 5 mg tablet 3.08USD tablet Midodrine hcl 5 mg tablet 2.47USD tablet Proamatine 2.5 mg tablet 1.53USD tablet Midodrine hcl 2.5 mg tablet 1.23USD tablet Apo-Midodrine 5 mg Tablet 0.59USD tablet Apo-Midodrine 2.5 mg Tablet 0.35USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 200 to 203°C Not Available water solubility Soluble Not Available logP -0.5 Not Available pKa 7.8 Not Available - Predicted Properties
Property Value Source Water Solubility 4.45 mg/mL ALOGPS logP -0.49 ALOGPS logP -0.95 ChemAxon logS -1.8 ALOGPS pKa (Strongest Acidic) 13.77 ChemAxon pKa (Strongest Basic) 8.14 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 93.81 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 66.22 m3·mol-1 ChemAxon Polarizability 26.65 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.7686 Blood Brain Barrier - 0.856 Caco-2 permeable - 0.7382 P-glycoprotein substrate Substrate 0.784 P-glycoprotein inhibitor I Non-inhibitor 0.9781 P-glycoprotein inhibitor II Non-inhibitor 0.9866 Renal organic cation transporter Non-inhibitor 0.8896 CYP450 2C9 substrate Non-substrate 0.8519 CYP450 2D6 substrate Non-substrate 0.7593 CYP450 3A4 substrate Non-substrate 0.5595 CYP450 1A2 substrate Inhibitor 0.8848 CYP450 2C9 inhibitor Non-inhibitor 0.9385 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Inhibitor 0.8993 CYP450 3A4 inhibitor Non-inhibitor 0.867 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9316 Ames test Non AMES toxic 0.774 Carcinogenicity Non-carcinogens 0.8613 Biodegradation Not ready biodegradable 0.9595 Rat acute toxicity 2.3137 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9772 hERG inhibition (predictor II) Non-inhibitor 0.8604
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as dimethoxybenzenes. These are organic aromatic compounds containing a monocyclic benzene moiety carrying exactly two methoxy groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Methoxybenzenes
- Direct Parent
- Dimethoxybenzenes
- Alternative Parents
- Phenoxy compounds / Anisoles / Alkyl aryl ethers / Secondary alcohols / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives / Aromatic alcohols
- Substituents
- P-dimethoxybenzene / Dimethoxybenzene / Phenoxy compound / Anisole / Phenol ether / Alkyl aryl ether / Secondary alcohol / Carboximidic acid / Carboximidic acid derivative / Ether
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- aromatic ether, amino acid amide, secondary alcohol (CHEBI:6933)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1A
- Uniprot ID
- P35348
- Uniprot Name
- Alpha-1A adrenergic receptor
- Molecular Weight
- 51486.005 Da
References
- Buckner SA, Milicic I, Daza AV, Meyer MD, Altenbach RJ, Williams M, Sullivan JP, Brioni JD: ABT-866, a novel alpha(1A)-adrenoceptor agonist with antagonist properties at the alpha(1B)- and alpha(1D)-adrenoceptor subtypes. Eur J Pharmacol. 2002 Aug 2;449(1-2):159-65. [PubMed:12163120]
- Taniguchi N, Hamada K, Ogasawara T, Ukai Y, Yoshikuni Y, Kimura K: NS-49, an alpha 1A-adrenoceptor agonist, selectively increases intraurethral pressure in dogs. Eur J Pharmacol. 1996 Dec 27;318(1):117-22. [PubMed:9007522]
- Altenbach RJ, Khilevich A, Kolasa T, Rohde JJ, Bhatia PA, Patel MV, Searle XB, Yang F, Bunnelle WH, Tietje K, Bayburt EK, Carroll WA, Meyer MD, Henry R, Buckner SA, Kuk J, Daza AV, Milicic IV, Cain JC, Kang CH, Ireland LM, Carr TL, Miller TR, Hancock AA, Nakane M, Esbenshade TA, Brune ME, O'Neill AB, Gauvin DM, Katwala SP, Holladay MW, Brioni JD, Sullivan JP: Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. J Med Chem. 2004 Jun 3;47(12):3220-35. [PubMed:15163201]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1B
- Uniprot ID
- P35368
- Uniprot Name
- Alpha-1B adrenergic receptor
- Molecular Weight
- 56835.375 Da
References
- Altenbach RJ, Khilevich A, Kolasa T, Rohde JJ, Bhatia PA, Patel MV, Searle XB, Yang F, Bunnelle WH, Tietje K, Bayburt EK, Carroll WA, Meyer MD, Henry R, Buckner SA, Kuk J, Daza AV, Milicic IV, Cain JC, Kang CH, Ireland LM, Carr TL, Miller TR, Hancock AA, Nakane M, Esbenshade TA, Brune ME, O'Neill AB, Gauvin DM, Katwala SP, Holladay MW, Brioni JD, Sullivan JP: Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. J Med Chem. 2004 Jun 3;47(12):3220-35. [PubMed:15163201]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Alpha1-adrenergic receptor activity
- Specific Function
- This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
- Gene Name
- ADRA1D
- Uniprot ID
- P25100
- Uniprot Name
- Alpha-1D adrenergic receptor
- Molecular Weight
- 60462.205 Da
References
- Altenbach RJ, Khilevich A, Meyer MD, Buckner SA, Milicic I, Daza AV, Brune ME, O'Neill AB, Gauvin DM, Cain JC, Nakane M, Holladay MW, Williams M, Brioni JD, Sullivan JP: N-[3-(1H-imidazol-4-ylmethyl)phenyl]ethanesulfonamide (ABT-866, 1),(1) a novel alpha(1)-adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine. J Med Chem. 2002 Sep 26;45(20):4395-7. [PubMed:12238918]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Proton-dependent oligopeptide secondary active transmembrane transporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
- Gene Name
- SLC15A1
- Uniprot ID
- P46059
- Uniprot Name
- Solute carrier family 15 member 1
- Molecular Weight
- 78805.265 Da
References
- Tsuda M, Terada T, Irie M, Katsura T, Niida A, Tomita K, Fujii N, Inui K: Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. Epub 2006 Apr 5. [PubMed:16597710]
Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:17